The Department for Health and Social Care has asked NICE to conduct an appraisal of selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2021 when we will write to you about how you can get involved.
These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.